Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.

Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW.

Leukemia. 2008 Jun;22(6):1184-90. doi: 10.1038/leu.2008.65. Epub 2008 Mar 20.

PMID:
18354488
2.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

3.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

4.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

5.

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.

Haematologica. 2005 Apr;90(4):534-41.

6.

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R.

Blood. 2005 Mar 1;105(5):2093-8. Epub 2004 Sep 2.

7.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.

Leukemia. 2002 Nov;16(11):2190-6.

8.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.

Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11.

9.

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.

Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.

Ann Hematol. 2006 Dec;85(12):841-7. Epub 2006 Sep 28.

PMID:
17006667
10.

Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.

Strhakova L, Bujalkova MG, Hojsikova I, Lukackova R, Behulova R, Mistrik M, Repiska V.

Neoplasma. 2011;58(6):548-53.

PMID:
21895409
11.

Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.

Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY, Wang MC, Lin TL, Lan YJ, Chen CC, Yang Y, Hsiao PC, Lai CL, Chang CH, Lin TH.

Leuk Res. 2013 Jan;37(1):43-9. doi: 10.1016/j.leukres.2012.09.012. Epub 2012 Oct 9.

PMID:
23062378
12.

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2002 Sep;16(9):1579-83.

13.

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ.

Blood. 2003 Jun 15;101(12):4701-7. Epub 2003 Feb 6.

14.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW.

Blood. 2010 Oct 28;116(17):3278-85. doi: 10.1182/blood-2008-10-183665. Epub 2010 Jun 2.

15.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

16.

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T.

Blood. 2003 Jul 1;102(1):276-83. Epub 2003 Mar 6.

17.

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.

Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.

Cancer. 2005 Apr 15;103(8):1659-69.

18.

[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].

Nausová J, Priwitzerová M, Jarosová M, Indrák K, Faber E, Divoký V.

Cas Lek Cesk. 2006;145(5):377-82. Czech.

PMID:
16755775
19.

Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.

Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.

Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.

20.

Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.

Miething C, Mugler C, Grundler R, Hoepfl J, Bai RY, Peschel C, Duyster J.

Leukemia. 2003 Sep;17(9):1695-9.

PMID:
12970766

Supplemental Content

Support Center